Topic: How To Invest

What is Pat’s commentary for the week of November 23, 2021

Article Excerpt

Dear Inner Circle Member, In July 2011 we analyzed Pfizer’s prospects and felt it offered our readers a strong combination of long-term growth and income. We—and you—have not been disappointed. The stock touched a new all-time high of $51.86 in August 2021, which is an impressive 159.3% above the $20 that the stock was trading for when we first recommended it in our Wall Street Stock Forecaster newsletter. To top it off, the dividend has jumped 95.0% since then. Much of Pfizer’s recent gains are due to the huge success of the two-shot COVID-19 vaccine that it developed with German drugmaker BioNTech. Many governments around the world—including Canada—have now approved the vaccine for children as young as five and as a third booster shot for most adults. Revenue from the vaccine will drop over the next two years as the pandemic eases. Even so, Pfizer’s new COVID-19 pill as a treatment medication will help offset some of that drop. Moreover, the company’s…

You are trying to access subscriber-only content.

To read this article, you may subscribe or sign in.
If you are already a subscriber, log in here.

If you wish to become a subscriber, click here. Or you may enjoy access to all our publications when you become a Member of Pat McKeough's Inner Circle Pro.